SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Popivanova B)
 

Search: WFRF:(Popivanova B) > Multicenter Interna...

  • Mlecnik, B (author)

Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer

  • Article/chapterEnglish2023

Publisher, publication year, extent ...

  • 2023-01-08
  • MDPI AG,2023

Numbers

  • LIBRIS-ID:oai:prod.swepub.kib.ki.se:152057611
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:152057611URI
  • https://doi.org/10.3390/cancers15020418DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background: The prognostic value of Immunoscore was evaluated in Stage II/III colon cancer (CC) patients, but it remains unclear in Stage I/II, and in early-stage subgroups at risk. An international Society for Immunotherapy of Cancer (SITC) study evaluated the pre-defined consensus Immunoscore in tumors from 1885 AJCC/UICC-TNM Stage I/II CC patients from Canada/USA (Cohort 1) and Europe/Asia (Cohort 2). METHODS: Digital-pathology is used to quantify the densities of CD3+ and CD8+ T-lymphocyte in the center of tumor (CT) and the invasive margin (IM). The time to recurrence (TTR) was the primary endpoint. Secondary endpoints were disease-free survival (DFS), overall survival (OS), prognosis in Stage I, Stage II, Stage II-high-risk, and microsatellite-stable (MSS) patients. RESULTS: High-Immunoscore presented with the lowest risk of recurrence in both cohorts. In Stage I/II, recurrence-free rates at 5 years were 78.4% (95%-CI, 74.4–82.6), 88.1% (95%-CI, 85.7–90.4), 93.4% (95%-CI, 91.1–95.8) in low, intermediate and high Immunoscore, respectively (HR (Hi vs. Lo) = 0.27 (95%-CI, 0.18–0.41); p < 0.0001). In Cox multivariable analysis, the association of Immunoscore to outcome was independent (TTR: HR (Hi vs. Lo) = 0.29, (95%-CI, 0.17–0.50); p < 0.0001) of the patient’s gender, T-stage, sidedness, and microsatellite instability-status (MSI). A significant association of Immunoscore with survival was found for Stage II, high-risk Stage II, T4N0 and MSS patients. The Immunoscore also showed significant association with TTR in Stage-I (HR (Hi vs. Lo) = 0.07 (95%-CI, 0.01–0.61); P = 0.016). The Immunoscore had the strongest (69.5%) contribution χ2 for influencing survival. Patients with a high Immunoscore had prolonged TTR in T4N0 tumors even for patients not receiving chemotherapy, and the Immunoscore remained the only significant parameter in multivariable analysis. CONCLUSION: In early CC, low Immunoscore reliably identifies patients at risk of relapse for whom a more intensive surveillance program or adjuvant treatment should be considered.

Added entries (persons, corporate bodies, meetings, titles ...)

  • Lugli, A (author)
  • Bindea, G (author)
  • Marliot, F (author)
  • Bifulco, C (author)
  • Lee, JKJ (author)
  • Zlobec, I (author)
  • Rau, TT (author)
  • Berger, MD (author)
  • Nagtegaal, ID (author)
  • Vink-Borger, E (author)
  • Hartmann, A (author)
  • Geppert, C (author)
  • Kolwelter, J (author)
  • Merkel, S (author)
  • Grutzmann, R (author)
  • Van den Eynde, M (author)
  • Jouret-Mourin, A (author)
  • Kartheuser, A (author)
  • Leonard, D (author)
  • Remue, C (author)
  • Wang, J (author)
  • Bavi, P (author)
  • Roehrl, MHA (author)
  • Ohashi, PS (author)
  • Nguyen, LT (author)
  • Han, S (author)
  • MacGregor, HL (author)
  • Hafezi-Bakhtiari, S (author)
  • Wouters, BG (author)
  • Masucci, GKarolinska Institutet (author)
  • Andersson, EK (author)
  • Zavadova, E (author)
  • Vocka, M (author)
  • Spacek, J (author)
  • Petruzelka, L (author)
  • Konopasek, B (author)
  • Dundr, P (author)
  • Skalova, H (author)
  • Nemejcova, K (author)
  • Botti, G (author)
  • Tatangelo, F (author)
  • Delrio, P (author)
  • Ciliberto, G (author)
  • Maio, M (author)
  • Laghi, L (author)
  • Grizzi, F (author)
  • Fredriksen, T (author)
  • Buttard, B (author)
  • Lafontaine, L (author)
  • Maby, P (author)
  • Majdi, A (author)
  • Hijazi, A (author)
  • El Sissy, C (author)
  • Kirilovsky, A (author)
  • Berger, A (author)
  • Lagorce, C (author)
  • Paustian, C (author)
  • Ballesteros-Merino, C (author)
  • Dijkstra, J (author)
  • van de Water, C (author)
  • Van Lent-van Vliet, S (author)
  • Knijn, N (author)
  • Musing, AM (author)
  • Scripcariu, DV (author)
  • Popivanova, B (author)
  • Xu, ML (author)
  • Fujita, T (author)
  • Hazama, S (author)
  • Suzuki, N (author)
  • Nagano, H (author)
  • Okuno, K (author)
  • Torigoe, T (author)
  • Sato, N (author)
  • Furuhata, T (author)
  • Takemasa, I (author)
  • Patel, P (author)
  • Vora, HH (author)
  • Shah, B (author)
  • Patel, JB (author)
  • Rajvik, KN (author)
  • Pandya, SJ (author)
  • Shukla, SN (author)
  • Wang, YL (author)
  • Zhang, GJ (author)
  • Kawakami, Y (author)
  • Marincola, FM (author)
  • Ascierto, PA (author)
  • Fox, BA (author)
  • Pages, F (author)
  • Galon, J (author)
  • Karolinska Institutet (creator_code:org_t)

Related titles

  • In:Cancers: MDPI AG15:22072-6694

Internet link

Find in a library

  • Cancers (Search for host publication in LIBRIS)

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view